Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Dogma-lysis: Dispelling Myths of the Intensive Care Unit

Posted on May 08, 2023
Patrick Costello, PharmD, BCCCP, Marc McDowell, PharmD, BCPS, and Poorvi Shah, PharmD, BCCCP

Author:
Patrick Costello, PharmD, BCCCP
Clinical Pharmacy Specialist –Medical Intensive Care Unit
University of Chicago Medicine

Author:
Marc McDowell, PharmD, BCPS
Clinical Assistant Professor
Department of Pharmacy Practice
UIC College of Pharmacy
Clinical Pharmacist
Medical Intensive Care Unit
Emergency Department
University of Illinois Hospital & Health Sciences System

Author:
Poorvi Shah, PharmD, BCCCP
Clinical Pharmacy Specialist
Medical Intensive Care Unit
Advocate Christ Medical Center


Disclosure(s):
Drs. Costello and Shah have no relevant financial conflicts of interest in relation to this activity. Dr. Marc McDowell is an investigator for a Takeda/Shire investigator-initiated grant. All of the relevant financial relationships listed for this individual have been mitigated. The reviewers who contributed to this activity have nothing to disclose.

Type of Activity: Knowledge-based

Learning Objectives:

  • Discuss how to interpret abnormalities of hemostasis and coagulopathy seen in critically ill patients with cirrhosis and describe how to design an appropriate pharmacologic treatment plan.
  • Describe outcomes comparing fixed to titrated dosing of neuromuscular blocking agents for acute respiratory distress syndrome.
  • Discuss the role of sodium bicarbonate for adult in-hospital cardiac arrest.
Target Audience: Pharmacists Fee: $10 (or $70 for all 10 courses). For C4 2022 participants who registered for the live program, please use the access code provided to you by email.
Release Date: September 19, 2022 Expiration Date: September 19, 2024
Estimated Time to Complete: 1 hour CE: 1.0 contact hours (0.1 CEUs)

Go to activity

acpe
Continuing Education Statement: The University of Illinois at Chicago College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been assigned ACPE Universal Activity Number 0016-0000-22-045-H01-P, for 1.0 contact hours (0.1 CEUs). Reading the learning objectives and faculty disclosures; participating in the entire knowledge-based activity, active learning activity, post-test and activity evaluation; estimating duration of time spent on the activity; and submitting NABP eProfile ID and MMDD are prerequisites for receiving continuing pharmacy education credits. All ACPE credit awarded to participants must be uploaded to CPE Monitor ™ within 30 days of the activity date, so pharmacists are required to provide their eProfile ID and date of birth (MMDD) at the time of the activity. Please contact pharmce@uic.edu if you do not see activity information listed within 30 days. For more information and to set up your e-Profile visit: https://nabp.pharmacy/programs/cpe-monitor/.

How to Earn Credit:

Participants must complete the activity as described above in the Continuing Education Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on ‘Finish Attempt’, then click on ‘Submit All and Finish’ at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test, a confirmation message will appear at the top of the page underneath your grade. You will have a chance to review the correct answers and answer rationale.

Hardware/Software and Internet Requirements can be found at https://pharmacyce.uic.edu/moodle/.

Provider Contact Information:
For general information or questions,  email the Office of Continuing Education and Meeting Services at pharmce@uic.edu. Copyright © 2023– The Board of Trustees of the University of Illinois. All rights reserved. Reproduction in whole or in part without permission is prohibited. Privacy Policy

Modified on May 08, 2023